AlphaFold

 

The structure of a protein is intricately linked to its function, and being able to predict this shape provides a deeper understanding of its role and mechanisms. Many global challenges, such as creating treatments for diseases or discovering enzymes that can degrade industrial waste, are fundamentally related to proteins and their functions \[1\] . This is where **"AlphaFold"** comes into play.

**What is AlphaFold ?**

AlphaFold is a groundbreaking solution by Google DeepMind aimed at solving the long-standing problem of protein structure prediction \[1\] . It leverages machine learning techniques to predict the three-dimensional structure of a protein based solely on its amino acid sequence.

**AlphaFold1:**

First introduced by DeepMind in 2018, AlphaFold1 was the team’s entry to the CASP13 competition, where it ranked first by providing the most accurate predictions for 25 out of 43 proteins \[4\]. The model produces predictions by estimating a distribution over possible spatial ranges of the protein's components \[2\].

**AlphaFold2:**

In December 2020, AlphaFold2 (AF2), a more advanced version developed by DeepMind, achieved a major victory at the 14th Critical Assessment of Structure Prediction (CASP14). AlphaFold2 works by taking the amino acid sequence of a new protein and aligning it with sequences of similar proteins \[3\]. It identifies regions of the sequence that tend to mutate together over evolutionary time, suggesting these regions are likely interacting and physically close in the protein's three-dimensional structure \[1\].

**AlphaFold3:**

In 2024, DeepMind, in collaboration with Isomorphic Labs, introduced AlphaFold3, which extends beyond proteins to predict the structures and interactions of a wide range of biomolecules, including DNA, RNA, and small molecules such as drugs. This advancement has the potential to revolutionize fields like drug design, genomics, the development of bio-renewable materials, and the creation of more resilient crops \[4\].

 

 

**Application of AlphaFold in Cancer Research:**

Artificial intelligence is revolutionizing drug discovery and development. In 2022, DeepMind's AlphaFold program achieved a remarkable milestone by accurately predicting the structures of proteins across the entire human genome, marking a major advancement in AI and structural biology \[5\]. This publicly accessible, AI-driven database allows scientists to determine the structures of millions of previously uncharacterized proteins, speeding up the creation of new treatments for various diseases and driving progress in numerous scientific fields. Its impact on cancer research is particularly profound, as it enhances understanding of cancer at the molecular level, aids in identifying new drug targets, and facilitates the development of more effective, personalized therapies, paving the way for new insights and breakthroughs in combating this complex disease.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Resources:

1\.       [How is AlphaFold2 used by scientists? | AlphaFold (ebi.ac.uk)](https://www.ebi.ac.uk/training/online/courses/alphafold/validation-and-impact/how-is-alphafold-used-by-scientists/)

2\.       Mohammed AlQuraishi, AlphaFold at CASP13, *Bioinformatics*, Volume 35, Issue 22, November 2019, Pages 4862–4865, [https://doi.org/10.1093/bioinformatics/btz422](https://doi.org/10.1093/bioinformatics/btz422)

3\.       Yang, Z., Zeng, X., Zhao, Y. *et al.* AlphaFold2 and its applications in the fields of biology and medicine. *Sig Transduct Target Ther* **8**, 115 (2023). [https://doi.org/10.1038/s41392-023-01381-z](https://doi.org/10.1038/s41392-023-01381-z)

4\.       [https://deepmind.google/discover/blog/alphafold-a-solution-to-a-50-year-old-grand-challenge-in-biology/](https://deepmind.google/discover/blog/alphafold-a-solution-to-a-50-year-old-grand-challenge-in-biology/)

5\.       [New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer \- ecancer](https://ecancer.org/en/news/22585-new-study-uses-alphafold-and-ai-to-accelerate-design-of-novel-drug-for-liver-cancer)

 

 

 

 

 

